Is the use of secukinumab after anti-TNF therapy greater than expected for the risk of developing inflammatory bowel disease? Fatih Albayrak, Mustafa Gür, Ahmet Karataş, Süleyman Serdar Koca, Bünyamin Kısacık

One-year retention rate of ixekizumab in patients with psoriatic arthritis and axial spondyloarthritis: Real-world data from the BIOBADASER registry Clementina López-Medina, Lucía Otero-Varela, Fernando Sánchez-Alonso, Vega Jovaní, Lorena Expósito-Pérez, Sheila Melchor-Díaz, Yanira Pérez-Vera, Paula Pretel-Ruiz, Javier Manero, Antonio Mera-Varela, Lourdes Mateo, Dolores Ruiz-Montesino, José Andrés Lorenzo-Martín, Teresa Pedraz-Penalva, Isabel Castrejón

Implementation of the recommendations for the psychological management of patients with spondyloarthritis and inflammatory bowel disease Ana Urruticoechea-Arana, Jesús Sanz, Daniel Ginard, Yago González-Lama, Xavier Juanola, Miriam Almirall, Natalia Borruel, Jordi Gratacós, Estíbaliz Loza